Sepsis fluid trial pulled before it even started
NCT ID NCT07191054
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study was designed to see if a device called LifeFlow could deliver fluids faster to children with sepsis compared to the usual push-pull method. The trial planned to include 600 children but was withdrawn before any participants were enrolled. No results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LifeFlow rapid infuser device
- What this could lead to
- If it had succeeded, this could have pointed toward faster, more efficient fluid delivery for children with sepsis, potentially improving outcomes.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data were collected. It is unclear if the device would have proven better or safer than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Phoenix Children's
Phoenix, Arizona, 85016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we optimize antibiotic dosing for children with sepsis?
- Could starting feeds sooner shield preterm babies from infection?
- Can brain waves predict thinking problems after sepsis?
- Can tailored nutrition boost recovery in the ICU?
- Blood markers may foretell brain fog after sepsis
- A hidden clue in the fingertips: could a pulse oximeter reading forecast sepsis outcomes?